FDA Approves First Regulatory T-Cell Therapy to Improve Stem Cell Transplants

The FDA has approved Tregzi, the first regulatory T-cell therapy (treatment that uses specialized immune cells to suppress abnormal immune responses) for adults with certain blood cancers who receive stem cell transplants from their matched donors. The treatment works by using regulatory T cells, which help control the immune system and reduce the risk of chronic graft-versus-host disease (GVHD), which when donated immune cells attack the patient's healthy tissues. In clinical trials, patients who received Tregzi experienced lower rates of chronic GVHD while the transplant was still able to fight the cancer. This approval is a major advancement in cell therapy and could improve both survival and quality of life for many patients.

My Perspective: I think this is a very exciting and useful breakthrough because it focuses on making stem cell transplants safer before instead of only treating issues after they happen. Since stem cell transplants can save lives but also come with serious risks, a therapy that helps the immune system work more effectively could make this treatment available to more patients. It also demonstrates how advances in cell therapy continue to change the future of cancer treatment.

Read the full story →

References

Weaver, Dr. C H. “FDA Approves the First Regulatory T-Cell Therapy to Improve Stem Cell Transplant Outcomes for Blood Cancers.” CancerConnect, 28 July 2026, news.cancerconnect.com/fda-approves-the-first-regulatory-t-cell-therapy-to-improve-stem-cell-transplant-outcomes-for-blood-cancers/

Subscribe to our newsletter

Receive weekly updates on recent cord blood banking and stem cell news.